An observational study in Ventilator Associated Pneumonia ( VAP), sponsored by University of Cambridge. Recruiting at 1 site in United Kingdom. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2025-08-03.
Sponsored by University of Cambridge · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom — 2 open to participants now, 3 under way, none of them phase 3. Pneumonia, Ventilator-Associated · United Kingdom.
Among the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom, this one is the only one that started in 2025, is one of 5 observational ones, and was the 11th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →2 of the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom are open now. Recruiting first, the newest first:
Cardiff and Vale University Health Board · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 1 Month to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 300 is above the median of 170 across 132 observational studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 182 across the 6 interventional studies, 250 across the 5 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 10 most frequent:
University of Cambridge is the lead sponsor of 116 studies on the registry; 23 are open to participants now.
University of Cambridge has 1 study filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumonia, Ventilator-Associated with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05719259European Clinical Research Alliance for Infectious Diseases (ECRAID)Perpetual Observational Study - Ventilator Associated Pneumonia | 2026-12-01 |
| NCT07026656University of CambridgePre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-associated Pneumonia in Critically Ill Children | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ventilator-associated pneumonia (VAP), defined as pneumonia occurring 48 hours after initiation of invasive mechanical ventilation, is insidious in onset and severe in consequence. It is a critical issue affecting 10-20% of the 26,000 children admitted to the paediatric intensive care unit (PICU) each year. Infection typically leads to extended PICU stay, prolonged invasive mechanical ventilation, and increased mortality.
Despite its clinical significance, VAP remains poorly defined, as current diagnosis relies on non-specific criteria and the ability to obtain clinically meaningful cultures. VAP, deviates from conventional pneumonia, potentially originating, from tissue damage, changes to immune processes, and migration of gastrointestinal bacteria into the lung; all associated with prolonged mechanical ventilation. These factors, in combination with the clinical instability of PICU patients, mean that clinicians aggressively start antibiotic therapy despite a paucity of evidence to suggest the best regime. As a result, suspected VAP has been shown to account for nearly 40% of antibiotic exposure in the PICU, which has significant implications on anti-microbial resistance (AMR).
To address these challenges, novel diagnostic therapies are needed to optimise the treatment of VAP. These therapies should utilise our current understanding of the pathophysiology of VAP development, specifically, the infiltration of the lung microbiome by gut and oral bacteria during prolonged mechanical ventilation. To achieve this, molecular testing should be promoted allowing for rapid identification of lung pathogens. There is also growing evidence, for the investigation of predictive biomarkers for VAP available in both the blood and lungs, which when integrated into protocols may enhance diagnostic accuracy. These novel techniques may improve clinical outcomes for affected children while addressing the economic impact of prolonged hospital stays and mitigating AMR risks in PICUs.
Critically Ill Children Requiring Mechanical Ventilation For Greater Than 48 Hours
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Critically ill children who develop VAP during their PICU journey will be assigned to the VAP group
All patients who fit eligibility criteria for study and do not go on to develop VAP
Characterise temporal shifts in microbial composition and the corresponding host immune response during prolonged mechanical ventilation
Serial metagenomic profiling of the lung microbiome to establish microbial shifts. Concurrently, cytokines collected from blood and endotracheal aspirates will be taken to assess immune changes.
Time frame: 3 years
Characterise the AMR burden in VAP and its role in shaping the microbiome during infection.
Utilise metagenomic sequencing to identify AMR genes present on microbes and relate this to VAP development
Time frame: 3 years
Develop statistical and/or machine learning models leveraging these signatures independently, or in combination, to identify putative microbial and host biomarkers for early VAP diagnosis
Time frame: 3 years
Prevalence of VAP
Number of critically ill children requiring mechanical ventilation who develop VAP compared to those who do not
Time frame: 3 years
30 day mortality
Mortality status of patients at 30 days
Time frame: 3 years
Time To Extubation
Total Time Intubated
Time frame: 3 years
Utilisation Of VAP Prevention Bundle
Time frame: 3 years
Culture Results
Microbiological Results For Each Patient
Time frame: 3 years
Days free of antimicrobial therapy in PICU at 7 days
Days free of antimicrobial therapy during the first 7 days of a patients admission to PICU
Time frame: 3 years
Plan to share: No — Patient data will be collected and stored on REDcap Safe Haven. All data that is shared will be anonymised to ensure it is not identifiable.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.
Of 63 non-industry observational studies under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 29 months is above that.
Counting every sponsor, half of 63 studies reached it within 20 months; a quarter within 12 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →